secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001558370-25-001517
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.02, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics loses China license for uproleselan; CEO, CFO, 5 directors depart
-------------------------------------------------------------------------------

- Apollomics terminated the collaboration license for uproleselan and GMI-1687 in China, effective 90 days from Feb 19, 2025.
- CEO Harout Semerjian and CFO Brian Hahn ceased employment on Feb 21, 2025; severance payments of $1,365,456 and $480,991 respectively.
- Five directors (Goldberg, Jackson, King, Koenig, Semerjian) resigned Feb 21, 2025; no disagreement with company operations.
- Semerjian consulting: $700/hr for 12 months; Hahn consulting: $15,000/month through change in control or Sep 30, 2025.
- Company is pursuing a merger with Crescent Biopharma (Form S-4 filed).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/glyc-20250219x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-001517

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer